SCI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SCI is not a good immediate buy for a Beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The business is fundamentally stable and analysts still lean positive, but the current technical setup is weak, there is no strong proprietary buy signal, and recent positioning data is not supportive enough to justify an aggressive purchase right now. I would hold off on buying at this pre-market level and wait for a clearer trend improvement.
SCI is in a short-term bearish trend. MACD histogram is negative and expanding, showing weakening momentum. RSI_6 at 29.715 is near oversold territory but not yet giving a strong reversal confirmation. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which confirms the broader trend is still under pressure. Current pre-market price of 76.78 is just above support at 76.049 and below pivot at 77.646, so the stock is trading near support but has not reclaimed a bullish level. The stock trend model also suggests downside risk over the next week and month.
["Analysts remain constructive overall, with JPMorgan maintaining Overweight and UBS maintaining Buy.", "Oppenheimer highlighted SCI's steady, relatively resilient growth and favorable long-term investment profile.", "The business is viewed as less sensitive to macro uncertainty and not meaningfully disrupted by AI.", "Options positioning is mildly bullish with call dominance in both open interest and volume.", "The stock is trading near support, which could provide a base if momentum improves."]
["No news in the recent week, so there is no fresh catalyst driving the stock higher.", "Technical trend is bearish: MACD is negative, moving averages are aligned bearishly, and momentum is weak.", "Price is below the pivot level, showing lack of near-term strength.", "Congress trading data shows 1 sale and 0 purchases in the last 90 days, which leans cautious.", "The stock trend model indicates meaningful downside probabilities over the next week and month.", "JPMorgan and UBS both lowered price targets recently, which softens the analyst enthusiasm."]
No financial snapshot was available due to an error, so latest quarterly revenue or earnings growth cannot be directly assessed from the provided data. The latest quarter season is not provided. Based on the analyst commentary, the company is still considered to have steady and resilient growth, but there is no current quarter financial data here to confirm recent execution.
Wall Street remains net positive, but target prices have been trimmed. JPMorgan lowered its target to $100 from $110 and kept Overweight on 2026-05-01. UBS lowered its target to $93 from $95 and kept Buy on 2026-05-01. Oppenheimer raised its target to $97 from $94 on 2026-04-02 and kept Outperform, citing resilient growth and a solid long-term profile. Overall, the pros still favor the stock, but recent target cuts show some moderation in upside expectations.
